- $53.70m
- $44.23m
- $1.12m
RenovoRx Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: RenovoRx Q1 Net Income USD -2.4 Million
RenovoRx Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Johns Hopkins Medicine Initiates Patient Enrollment For Renovorx’S Ongoing Phase III Tiger-Pac Clinical Trial
Brief: Renovorx Increases U.S. Production Of Renovocath Devices To Meet Growing Demand From Oncology Community
RenovoRx Inc reports results for the quarter ended December 31 - Earnings Summary
RenovoRx Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Renovorx Announces Pricing Of $12.1 Million Underwritten Public Offering Of Common Stock
Brief: Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial
RenovoRx Inc reports results for the quarter ended in June - Earnings Summary
Brief: Renovorx Appoints Ryan Witt As Senior Vice President, Head Of Corporate Strategy And Partnerships
RenovoRx Inc reports results for the quarter ended in January - Earnings Summary
RenovoRx Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: RenovoRx Announces $11.1 Mln At Market Private Placement
RenovoRx Inc reports results for the quarter ended in December - Earnings Summary
RenovoRx Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Renovorx Says On February 21, Co Got Notice From Nasdaq
Brief: Renovorx Says James Ahlers Provided Notice To Co Of His Resignation As Chief Financial Officer, Effective Immediately